Compare Amphastar Pharmaceuticals Inc (AMPH) vs Freshworks Inc (FRSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Freshworks Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Freshworks Inc trades at $10.45 (market cap $2.86B). The key difference: Freshworks Inc is far larger — about 3.5× Amphastar Pharmaceuticals Inc's market cap, and Freshworks Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | FRSH | |
|---|---|---|
Market Cap | $826.08M | $2.86B |
Sector | Health | Technology |
52-Week High | $30.81 | $14.77 |
52-Week Low | $16.87 | $6.88 |
Enterprise Value | $1.22B | $2.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
FRSH trades at $10.36, down 0.38% on the day, with a bullish technical signal from moving averages and an overall analyst consensus split evenly between Buy and Hold. The company reported strong revenue growth to $838.81M in 2025, turning profitable with a net income of $183.72M, and recently announced Q2 2026 earnings will be released on August 4, 2026. Recent news highlights include a partnership with Vanquis and AI product enhancements.
Outlook remains positive with Wall Street projecting a 26% upside, supported by robust cash flow and margin expansion. Key risks include competitive pressures in SaaS and execution on AI initiatives. The stock presents a value opportunity given its P/E of 16.86 versus sector averages, but investors should monitor Q2 earnings for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
